Evidence map›Paper›PMID 37401847›Full record

ArticleJournal of veterinary internal medicine

Fecal acute phase proteins in cats with chronic enteropathies.

Dimitra A Karra, Chris C Chadwick, Evangelia M Stavroulaki, Matina N Pitropaki, Evgenia Flouraki, Karin Allenspach, Jonathan A Lidbury, Joerg M Steiner, Panagiotis G Xenoulis

Open access · goldAbstract read
In one paragraph

Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Dimitra A KarraUniversity of Thessaly, Small Animal Clinic, Karditsa, Greece.ORCID https://orcid.org/0000-0002-7505-7816
Chris C ChadwickLife Diagnostic Inc., West Chester, Pennsylvania, USA.
Evangelia M StavroulakiUniversity of Thessaly, Small Animal Clinic, Karditsa, Greece.
Matina N PitropakiUniversity of Thessaly, Small Animal Clinic, Karditsa, Greece.
Evgenia FlourakiUniversity of Thessaly, Small Animal Clinic, Karditsa, Greece.
Karin AllenspachIowa State University, College of Veterinary Medicine, Veterinary Clinical Sciences, Ames, Iowa, USA.ORCID https://orcid.org/0000-0002-2168-5809
Jonathan A LidburyTexas A&M University - Gastrointestinal Laboratory, College of Veterinary Medicine & Biomedical Sciences, College Station, Texas, USA.ORCID https://orcid.org/0000-0001-5107-4577
Joerg M SteinerTexas A&M University, Gastrointestinal Laboratory, College Station, Texas, USA.ORCID https://orcid.org/0000-0003-3336-2086
Panagiotis G XenoulisUniversity of Thessaly, Small Animal Clinic, Karditsa, Greece.ORCID https://orcid.org/0000-0002-9508-0271
University of Thessaly · GRIowa State University · USTexas A&M University · USTexas College · USWest Chester University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic enteropathies (CE) are common in cats and reliable biomarkers that can distinguish different causes and predict or monitor response to treatment are currently lacking. HYPOTHESIS: To evaluate certain acute phase proteins in feces that could potentially be used as biomarkers in cats with CE. ANIMALS: Twenty-eight cats with either inflammatory bowel disease (IBD; n = 13), food-responsive enteropathy (FRE; n = 3) or small cell gastrointestinal lymphoma (SCGL; n = 12) and 29 healthy control cats were prospectively enrolled.

methodsFecal concentrations of haptoglobin, alpha-1-acid-glycoprotein (AGP), pancreatitis-associated protein-1 (PAP-1), ceruloplasmin, and C-reactive protein (CRP) were measured using Spatial Proximity Analyte Reagent Capture Luminescence (SPARCL) immunoassays before and after initiation of treatment. Cats were treated with diet and/or prednisolone (IBD cats), plus chlorambucil (SCGL cats).

resultsCompared with controls, median fecal AGP concentrations were significantly lower (25.1 vs 1.8 μg/g; P = .003) and median fecal haptoglobin (0.17 vs 0.5 μg/g), PAP-1 (0.04 vs 0.4 μg/g) and ceruloplasmin (0.15 vs 4.2 μg/g) concentrations were significantly higher (P < .001) in cats with CE. Median fecal AGP concentrations were significantly lower (P = .01) in cats with IBD and FRE (0.6 μg/g) compared with cats with SCGL (10.75 μg/g). A significant reduction was found in CE cats after treatment for median fecal ceruloplasmin concentrations (6.36 vs 1.16 μg/g; P = .04).

conclusionsFecal AGP concentration shows promise to differentiate cats with SCGL from cats with IBD and FRE. Fecal ceruloplasmin concentrations may be useful to objectively monitor response to treatment in cats with CE.

Indexed as

Cat DiseasesInflammatory Bowel DiseasesLeukemia, Lymphocytic, Chronic, B-CellAcute-Phase ProteinsAnimalsBiomarkersCatsCeruloplasminFecesHaptoglobinsAcute-Phase ProteinsBiomarkersCeruloplasminHaptoglobinsAGPceruloplasminfecal biomarkershaptoglobinPAP-1

Identifiers

PMID37401847
PMCPMC10473003
OpenAlexW4383058944

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.